AstraZeneca: two trials give positive results

  •   15/06/2020 - 11h25
  •   DEHOUI Lionel

AstraZeneca is a multinational biopharmaceutical and pharmaceutical company headquartered in Cambridge, England. The group works on major disease areas such as: gastrointestinal, cardiovascular, cancer, respiratory tract, inflammation, infections and neuroscience. It was founded in 1999 with the merger between the Swedish group Astra AB and its British neighbour Zeneca. Over the years, AstraZeneca has become one of the world's largest pharmaceutical companies. The group has a listing on the London Stock Exchange as well as being part of the FTSE 100 Index and has secondary listings on both the OMX and New York Stock Exchanges. Today, the AstraZeneca group is conducting several studies to find effective treatments for certain diseases such as: chronic lymphocytic leukemia. Moreover the pharmaceutical giant has made a rather special announcement concerning the treatment of this kind of leukaemia.

Trade Astrazeneca shares!
76.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
AstraZeneca: two trials give positive results
Image copyright: Gwan Kho - Flickr

The results of the tests

AstraZeneca released its results for Calquence solution which was in the midst of testing. Indeed, Calquence has demonstrated tolerance and long-term efficacy for patients suffering from chronic lymphocytic leukemia. This result is obtained after two trials depending on the group. The overall response rate in the ACE-CL-001 trial is 97% and has a durable safety profile.

The biopharmaceutical group clarified on Friday that this fact is observed for patients not previously treated after more than 4 years. Another very decisive and important precision is delivered by the latest ASCEND analysis. According to this analysis, nearly 82% of people with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) who received treatment with Calquence survived. They are even spared disease progression at 18 months.

Information: For patients treated with rituximab in combination with idelalisib or bendamustine, 48% remained alive.


The plausible solution for patients

These various results have led the Director of the CLL Research Center (Weill Cornell Medicine), Mr. Richard R. Furman, to give his opinion. He said the safety profile of acalabrutinib demonstrates that it remains a plausible and important treatment option for patients through to progression.

From now on, all eyes interested in these results have focused on the events taking place from 11 to 14 June 2020. Indeed, the European Haematology Association (EHA) held its 25th annual congress during which the results of research conducted by AstraZeneca were presented.


AstraZeneca in discussion for a coronavirus vaccine

The day after the announcement of these results on the treatment of CLL, on Saturday, the CEO of AstraZeneca made a statement. He said his team is in discussions with some countries to supply them with his Covid-19 vaccine proposal. He cited Brazil, Japan, Russia and China, among others.

Similarly, the group is about to make public the results obtained from the first phase of tests on its invention. It should also be noted that the pharmaceutical group AstraZeneca has concluded an agreement with the European Union to supply up to 400 million doses of the said vaccine.